Highlights•60 million people globally have chronic kidney disease•Early detection is key to avoiding death due to related cardiovascular disease or end-stage renal disease•Simple urine dipstick test for protein correctly identified those at risk; is less expensive than other tests
Newswise — Washington, DC (July 29, 2011) — A simple and inexpensive urine test routinely done in family doctors’ offices may be the key to identifying individuals who are silently undergoing rapid kidney function decline, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). Using this test could lead to potentially earlier and more effective treatments, lowering patients’ risks of developing kidney failure and dying prematurely.
Approximately 60 million people globally have chronic kidney disease. Early detection and prevention of kidney disease is the only way to prevent kidney failure, but individuals with kidney disease often do not experience symptoms until later stages of the disease. Serial monitoring of kidney function in the general population would likely catch such silently progressing kidney disease early, but it would be too expensive.
William Clark, MD (University of Western Ontario and London Health Sciences Centre, in London, Canada) and his colleagues evaluated whether simple and routine screening tests for urine protein could be used to identify individuals at highest risk of rapid kidney function decline. These patients would benefit the most from serial kidney function monitoring and early treatments to prevent kidney failure.
The investigators followed 2,574 participants in a community-based clinic for an average of seven years. They found that a positive dipstick urine test (a protein concentration of ≥1g/L) was a strong predictor of rapid kidney function decline. Overall, 2.5% of participants in the study had a urinary protein concentration of ≥1g/L at the start of the study. If all of them were followed with serial monitoring of kidney function, one case of rapid kidney function decline would be identified for every 2.6 patients who were followed.
The test correctly identified whether or not individuals had rapid kidney function decline in 90.8% of participants, mislabeled 1.5% as having the condition, and missed 7.7% who were later identified as having the condition. Among those with certain risk factors (cardiovascular disease, age >60 years, diabetes, or hypertension), the probability of identifying rapid kidney function decline from serial kidney function measurements increased from 13% to 44% after incorporating a positive dipstick test.
“We showed that routine inexpensive urine dipstick screening in a population with and without risk factors will allow primary clinicians to follow fewer patients with serial monitoring to identify those with rapid kidney function decline that will potentially benefit from earlier referral and therapeutic intervention,” said Dr. Clark.
Study co-authors include Jennifer Macnab, PhD, Louise Moist, MD (University of Western Ontario, in London, Canada); Marina Salvadori, MD (London Health Sciences Centre, in London, Canada); Jessica Sontrop, PhD, Arsh Jain, MD, Rita Suri, MD, and Amit Garg, MD, PhD (University of Western Ontario and London Health Sciences Centre, in London, Canada).
Disclosures: This work was funded by peer-review grants from Kidney Foundation of Canada and the Ontario Ministry of Health. Amit Garg was supported by a Canadian Institute Health Research career investigator award.
The article, entitled “Dipstick Proteinuria as a Screening Strategy to Identify Rapid Renal Decline,” will appear online at http://jasn.asnjournals.org/ doi 10.1681/ASN.2010111217
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 12,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.